Company History Timeline — 2020s


  • Agilent receives FDA approval for PD-L1 IHC 22C3 pharmDx in Triple-Negative Breast Cancer, marking the seventh cancer type for which the companion diagnostic gains approval in the US.

  • Agilent launches its first-ever instrument subscription program, becoming a leader in lab customer excellence and technology services delivery. It also introduces CrossLab Connect services for lab-wide asset monitoring and the 7850 ICP-MS System that improves ICP-MS analysis workflows.

  • Agilent is one of the earliest champions and sponsors of My Green Lab, a nonprofit organization that provides certified sustainability labels to lab instruments, giving customers insight into the environmental footprint of their purchases.

  • Net revenue: $5.34 billion; employees: 16,400.


  • Agilent launches three InfinityLab Bio LC systems, completing a solution of instruments, columns, and supplies that seamlessly integrate with Agilent OpenLab and MassHunter software, and CrossLab services. This further maximizes the efficiency of Agilent's biopharma customers.

  • For a third consecutive year, Agilent is ranked in the top three of Barron's Most Sustainable Companies in America, a distinction that recognizes environmental leadership in our operations, our products, and our supply chain.

  • Agilent names Katharine Knobil, M.D., the company's first chief medical officer, a newly created position to advise, lead, and elevate Agilent's presence in the heath-care industry.

  • Agilent and Visopharm expand their collaboration with a worldwide distribution agreement, marking Agilent's first entry into the growing digital pathology market by leveraging artificial intelligence and remote reporting capabilities.

  • Building on decades of corporate social responsibility initiatives and public reporting, Agilent commits to reaching net-zero emissions by 2050.


  • Agilent introduces the 6475 triple quadrupole LC/MS system, 5977C GC/MSD, 7000E GC/TQ and 7010C GC/TQ, representing a significant advancement in Agilent's 50-plus year history in mass spectrometry. The new LC/TQ and GC/TQ products offer built-in instrument intelligence to simplify lab operations. The new GC/SQ and GC/TQ products with the HydroInert source help customers overcome performance challenges with hydrogen carrier gas.

  • Agilent continues to expand its end-to-end lab solutions by acquiring powerful AI and machine learning software for GC/MS platforms, and hardware and software solutions for the analysis of natural and synthetic polymers.

  • Agilent is ranked among the top 20 companies in customer satisfaction by the Wall Street Journal's list of the 250 Best-Managed Companies.


  • Agilent announces a doubling of manufacturing capacity of nucleic acid-based therapeutics to meet growing demand for the company's high-quality therapeutic oligonucleotides that serve as the API for drugs that target diseases such as cancer, cardiovascular disease, and rare and infectious diseases.

  • Agilent achieves Great Place to Work® certification in all countries and territories eligible for the distinction, including the U.S. An overwhelming majority of employees indicate a strong level of satisfaction with the company.

  • Agilent releases a full workflow for targeted PFAS analysis, a solution that brings substantial efficiency gains to a labor-intensive testing process. The solution comes at a critical time of growing concern about the buildup of PFAS in the environment.


< Back